Loading clinical trials...
Loading clinical trials...
Telomere Repair Gene Mutations in Inflammatory Bowel Disease
This study will evaluate and compare the genes of the telomere repair complex in healthy control subjects, patients with blood diseases, and patients with inflammatory bowel disease to identify what, if any, changes are associated specifically with inflammatory bowel disease. Patients between 2 and 80 years of age with ulcerative colitis or regional enteritis may be eligible for this study. Participants are recruited from the practice of Dr. Stuart Danovitch, Washington, D.C. Researchers have established that minor differences in a specific set of genes called the telomere repair complex are related to immune-mediated diseases of the bone marrow. NIH researchers are now interested in whether inflammatory bowel disease and other autoimmune diseases show a similar pattern of genetic differences. Participants provide a cell sample for evaluation of the telomere repair complex. The sample is collected via buccal swab, a gentle scraping of the inside of the cheek, and stored for use in research.
We have identified inherited mutations in genes of the telomere repair complex in patients with acquired aplastic anemia. These mutations diminish the ability of cells to repair the ends of chromosomes, called telomeres, which normally shorten with each cell division. Mutations in TERC, the gene which encodes for the RNA template of the complex; in TERT, the gene for the enzyme in the complex, and also in the Schwachman-Bodian-Diamond syndrome gene (SBDS), which we believe to be associated with telomere repair, lead to reduced telomerase activity, diminished numbers of hematopoietic cells in the bone marrow, and presumably also a deficiency in the ability of cells to respond to immunological attack and destruction of the hematopoietic system. This laboratory research protocol will allow us to evaluate whether similar gene mutations might underlie other autoimmune diseases, here specifically, inflammatory bowel disease, which share broad pathophysiologic features with immune-mediated aplastic anemia. We will directly assess by DNA sequencing suspect genes (TERC, TERT, SBDS, DNA helicases and others) in buccal mucosal samples obtained from patients with inflammatory bowel disease (IBD). Analyses from large numbers of controls have defined polymorphisms for these genes. IBD samples will allow us to determine whether mutations in these genes are more prevalent in this patient population and to test the hypotheses that telomere repair defects underlie human autoimmunity, or that these genes are specifically involved in hematology as risks factors for bone marrow failure.
Age
2 - 80 years
Sex
ALL
Healthy Volunteers
No
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Start Date
May 15, 2006
Primary Completion Date
May 15, 2006
Completion Date
May 21, 2020
Last Updated
May 22, 2020
95
ACTUAL participants
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NCT06226883
NCT07207200
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07245394